[關(guān)鍵詞]
[摘要]
抗血小板藥物是目前治療缺血性心臟病的常用藥物，主要包括氯吡格雷、阿司匹林，但易發(fā)生氯吡格雷抵抗、阿司匹林抵抗，而它們同屬于抗凝治療后血小板高反應(yīng)性的范疇。遺傳因素對血小板高反應(yīng)性的影響至關(guān)重要。目前對血小板高反應(yīng)性的治療策略主要以個體化抗血小板治療為主，常用的藥物包括替格瑞洛、αIIbβ3拮抗劑、中藥?？偨Y(jié)了血小板高反應(yīng)性的遺傳因素和治療策略的研究進(jìn)展，旨在為血小板高反應(yīng)性的治療提供臨床參考。
[Key word]
[Abstract]
Antiplatelet drugs are currently commonly used in the treatment of ischemic heart disease, mainly including clopidogrel and aspirin. However, they are easy to develop clopidogrel resistance and aspirin resistance, both of which belong to high on-treatment platelet reactivity after anticoagulation therapy. The influence of genetic factors on high on-treatment platelet reactivity is crucial. At present, personalized antiplatelet therapy is the main treatment strategy for high on-treatment platelet reactivity, and commonly used drugs include ticagrelor, αIIbβ3 antagonists, and traditional Chinese medicine. This article summarizes the research progress on genetic factors and treatment strategies of high on-treatment platelet reactivity, to provide clinical reference for the treatment of high on-treatment platelet reactivity.
[中圖分類號]
R973
[基金項目]
安徽高校自然科學(xué)研究項目（KJ2021A0342）;安徽醫(yī)科大學(xué)?？蒲谢痦椖浚?022xkj100）;六安市科技計劃項目（2022lakj034）
